Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Precipitate Formation and Particle Size Control

Precipitate Formation and Particle Size Control

In precipitation gravimetry, the precipitating agent should react specifically or selectively with the analyte. While a specific reagent reacts with the analyte alone, a selective reagent can react with a limited number of chemical species.
The obtained precipitate should be either a pure substance of known composition or easily converted to one by a simple process, such as ignition or drying. In addition, the precipitate should be insoluble and easily filterable. In general, filterability...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Methods of Medium Optimization

Methods of Medium Optimization

Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sub-50 nm ultra-small organic drug nanosuspension prepared by cavi-precipitation and its brain targeting potential.

International journal of pharmaceutics·2021

Same author

Can the cavi-precipitation process be exploited to generate smaller size drug nanocrystal?

Drug development and industrial pharmacy·2021

Same author

Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC).

International journal of pharmaceutics·2019

Same author

BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products.

Beilstein journal of nanotechnology·2019

Same author

Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery.

Drug delivery·2019

Same author

Dermal smartPearls - Optimized silica particles for commercial products & mechanistic considerations.

International journal of pharmaceutics·2019

Search research articles

Related Experiment Video

Updated: May 13, 2026

Processing of Bulk Nanocrystalline Metals at the US Army Research Laboratory

Processing of Bulk Nanocrystalline Metals at the US Army Research Laboratory

Published on: March 7, 2018

Performance comparison of two novel combinative particle-size-reduction technologies.

Jaime Salazar¹, Rainer H Müller, Jan P Möschwitzer

¹Institute of Pharmacy, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität Berlin, Berlin 12169, Germany.

Journal of Pharmaceutical Sciences

|February 26, 2013

Summary

This summary is machine-generated.

Combinative technologies enhance drug nanosizing for better bioavailability. The H 42 process, combining spray drying and high-pressure homogenization (HPH), effectively reduced glibenclamide particle size to 236 nm.

More Related Videos

A System to Create Stable Nanoparticle Aerosols from Nanopowders

A System to Create Stable Nanoparticle Aerosols from Nanopowders

Published on: July 26, 2016

Precise Electrochemical Sizing of Individual Electro-Inactive Particles

Precise Electrochemical Sizing of Individual Electro-Inactive Particles

Published on: August 4, 2023

Related Experiment Videos

Last Updated: May 13, 2026

Processing of Bulk Nanocrystalline Metals at the US Army Research Laboratory

Processing of Bulk Nanocrystalline Metals at the US Army Research Laboratory

Published on: March 7, 2018

A System to Create Stable Nanoparticle Aerosols from Nanopowders

A System to Create Stable Nanoparticle Aerosols from Nanopowders

Published on: July 26, 2016

Precise Electrochemical Sizing of Individual Electro-Inactive Particles

Precise Electrochemical Sizing of Individual Electro-Inactive Particles

Published on: August 4, 2023

Area of Science:

Pharmaceutical Technology
Materials Science
Drug Delivery

Background:

Nanosizing poorly soluble drugs improves dissolution and bioavailability.
Conventional methods like high-pressure homogenization (HPH) have limitations in achieving desired particle sizes.
Combinative approaches integrate bottom-up and top-down techniques to overcome these limitations.

Purpose of the Study:

To evaluate the efficacy of the H 42 combinative technology for drug nanosizing.
To investigate the impact of spray drying and HPH on glibenclamide particle size and distribution.
To compare the H 42 process with the H 96 technology for nanocrystal production.

Main Methods:

The H 42 process involved dissolving glibenclamide in ethanol with varying surfactant concentrations.
Spray drying was used to create drug powders, followed by high-pressure homogenization (HPH).
Particle size was analyzed using photon correlation spectroscopy and laser diffractometry.

Main Results:

The H 42 process successfully produced nanosuspensions with reduced particle size and narrower distribution compared to unmodified glibenclamide.
The optimal sample achieved a mean particle size of 236 nm after 20 HPH cycles.
Laser diffractometry showed D50 and D90 values of 0.131 µm and 0.285 µm, respectively.

Conclusions:

Both H 42 and H 96 combinative technologies are effective for producing very small drug nanocrystals.
The precipitation step in combinative methods yields a brittle material suitable for subsequent homogenization.
These advanced techniques offer improved formulation strategies for poorly soluble drugs.